Altium Capital Management LP Tcr2 Therapeutics Inc. Transaction History

Altium Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $270,907 - $493,311	-59,150 Closed	0 $0
Q3 2021 Nov 17, 2021	BUY	$8.44 - $18.35 $499,225 - $1.09 Million	59,150 New	59,150 $503,000
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $1.77 Million - $3.84 Million	-209,130 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$20.38 - $34.07 $2.75 Million - $4.6 Million	135,139 Added 182.64%	209,130 $4.62 Million
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $1.41 Million - $2.41 Million	73,991 New	73,991 $2.29 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.